Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026)
Ardelyx posted quarterly Non-Current Deffered Revenue of $13.7 million for Q1 2026, up 64.06% year-on-year from $8.4 million in Q1 2025, and little changed on a QoQ basis from $13.7 million in Q4 2025.
Ardelyx (ARDX) has 9 years of Non-Current Deffered Revenue data on file, last reported at $13.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 64.06% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 64.06% YoY), and the FY2025 full-year result was $13.7 million, up 89.42% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $13.7 million, roughly flat from $13.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $13.7 million in Q3 2025 and bottomed at $7.2 million in Q4 2024.
- The 5-year median for Non-Current Deffered Revenue is $10.3 million (2023), against an average of $10.7 million.
- The widest annual swing landed in 2022, when Non-Current Deffered Revenue soared 321.48%; it then tumbled 31.01% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $9.0 million in 2022, then fell by 4.22% to $8.6 million in 2023, then declined by 16.34% to $7.2 million in 2024, then jumped by 89.42% to $13.7 million in 2025, then changed by 0.0% to $13.7 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $13.7 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 13.70 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 12.77 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Dec 31, 2023 | 8.64 Mn |
| Sep 30, 2023 | 10.29 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 11.50 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 8.56 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 8.56 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 2.95 Mn |
| Mar 31, 2021 | 2.95 Mn |
| Mar 31, 2015 | 27.19 Mn |
| Dec 31, 2014 | 31.07 Mn |
| Sep 30, 2014 | 34.96 Mn |
| Jun 30, 2014 | 33.17 Mn |
| Dec 31, 2013 | 26.47 Mn |